Baclofen for alcohol withdrawal
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing and life-threatening condition that usually affects people who are alcohol dependent when they discontinue or decrease their alcohol consumption. Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review first published in 2011 and last updated in 2017. OBJECTIVES: To assess the efficacy and safety of baclofen for people with AWS. SEARCH METHODS: We updated our searches of the following databases to June 2019: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language. SELECTION CRITERIA: We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included four RCTs with 189 randomised participants (one RCT new for this update). None of the included studies reported the primary outcomes of alcohol withdrawal seizures, alcohol withdrawal delirium, or craving. For the comparison of baclofen and placebo (1 study, 31 participants), there was no evidence of a difference in Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) scores in eight-hour periods from days one to five (very low-quality evidence). For the comparison of baclofen and diazepam (2 studies, 85 participants), there was no evidence of a difference in change from baseline to days 10 to 15 on CIWA-Ar scores (very low-quality evidence, meta-analysis was not performed due to insufficient data). In one study (37 participants), there was no evidence of a difference in participants with at least one adverse event (risk difference (RD) 0.00, 95% confidence interval (CI) -0.10 to 0.10; very low-quality evidence), dropouts (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence). For the comparison of baclofen and chlordiazepoxide (1 study, 60 participants), there was no evidence of a difference in difference from baseline to nine-day decremental fixed-dose intervention: CIWA-Ar scores (mean difference (MD) 1.00, 95% CI 0.70 to 1.30; very low-quality evidence), global improvement (MD 0.10, 95% CI -0.03 to 0.23; very low-quality evidence), 14/60 participants with adverse events (RD 2.50, 95% CI 0.88 to 7.10; very low-quality of evidence), dropouts (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence). None of the RCTs provided information on random sequence generation or allocation concealment, therefore, we assessed them at unclear risk of bias. Two RCTs were not of double-blind design and had a high risk of bias in blinding (Addolorato 2006; Girish 2016). One RCT had more than 5% dropouts with high risk of attrition bias (Lyon 2011). We could not assess reporting bias as none of the prepublished protocols were available. AUTHORS' CONCLUSIONS: No conclusions can be drawn about the efficacy and safety of baclofen for the management of alcohol withdrawal because we found insufficient and very low-quality evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Benzodiazepines for alcohol withdrawal
Amato, L., Minozzi, S., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005063.pub3 · Cited by 245
Baclofen in the Treatment of Alcohol Withdrawal Syndrome: A Comparative Study vs Diazepam
Addolorato, G., Leggio, L., Abenavoli, L., Agabio, R., Caputo, F., Capristo, E., Colombo, G., Gessa, G. L., & Gasbarrini, G. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.08.042 · Cited by 203
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence
Gupta, M., Verma, P., Rastogi, R., Arora, S., & Elwadhi, D. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1240797 · Cited by 26
Baclofen for alcohol withdrawal
Liu, J., & Wang, L.-N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008502.pub4 · Cited by 26
Self-citationBaclofen and the Alcohol Withdrawal Syndrome—A Short Review
Cooney, G., Heydtmann, M., & Smith, I. D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00773 · Cited by 24
Research works printed but not linked: 52
- Girish, 2016, A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome, Biomedical Journal, 39, 72, 10.1016/j.bj.2015.09.002 · DOI · Paper page
- Lyon, 2011, Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial, Journal of Hospital Medicine, 6, 469, 10.1002/jhm.928 · DOI · Paper page
- Addolorato, 2002, Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study, Alcohol and Alcoholism (Oxford, Oxfordshire), 37, 504, 10.1093/alcalc/37.5.504 · DOI · Paper page
- Addolorato, 2007, Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study, Lancet, 370, 1915, 10.1016/S0140-6736(07)61814-5 · DOI · Paper page
- Addolorato, 2011, Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial, Alcohol and Alcoholism (Oxford, Oxfordshire), 46, 312, 10.1093/alcalc/agr017 · DOI · Paper page
- Beraha, 2016, Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial, European Neuropsychopharmacology, 26, 1950, 10.1016/j.euroneuro.2016.10.006 · DOI
- Farokhnia, 2015, Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial, Neuropsychopharmacology, 40, 1560, 10.1038/npp.2015.29 · DOI
- Franchitto, 2014, Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series, Alcohol and Alcoholism (Oxford, Oxfordshire), 49, 79, 10.1093/alcalc/agt169 · DOI · Paper page
- Garbutt, 2007, Baclofen for alcoholism, Lancet, 370, 1884, 10.1016/S0140-6736(07)61789-9 · DOI
- Garbutt, 2010, Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial, Alcoholism, Clinical and Experimental Research, 34, 1849, 10.1111/j.1530-0277.2010.01273.x · DOI · Paper page
- Geisel, 2016, Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen, Psychiatry Research, 240, 177, 10.1016/j.psychres.2016.04.007 · DOI
- Hauser, 2017, The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized clinical trial, Addiction, 112, 1173, 10.1111/add.13787 · DOI · Paper page
- Imbert, 2015, Anticraving effect of baclofen in alcohol- dependent patients, Alcoholism, Clinical and Experimental Research, 39, 1602, 10.1111/acer.12823 · DOI
- Krupitsky, 1993, Baclofen administration for the treatment of affective disorders in alcoholic patients, Drug and Alcohol Dependence, 33, 157, 10.1016/0376-8716(93)90057-W · DOI
- Krupitsky, 1995, Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov, 95, 67
- Krupitsky, 2015, Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov, 115, 53, 10.17116/jnevro20151156153-62 · DOI
- Leggio, 2012, Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection, Addictive Behaviors, 37, 561, 10.1016/j.addbeh.2011.12.010 · DOI · Paper page
- Leggio, 2013, A human laboratory pilot study with baclofen in alcoholic individuals, Pharmacology, Biochemistry, and Behavior, 103, 784, 10.1016/j.pbb.2012.11.013 · DOI · Paper page
- Morley, 2013, The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial, Contemporary Clinical Trials, 36, 348, 10.1016/j.cct.2013.08.002 · DOI
- Müller, 2015, High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial, European Neuropsychopharmacology, 25, 1167, 10.1016/j.euroneuro.2015.04.002 · DOI · Paper page
- Pommier, 2014, Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study, Basic & Clinical Pharmacology & Toxicology, 114, 360, 10.1111/bcpt.12161 · DOI
- Ponizovsky, 2015, Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up, Journal of Substance Abuse Treatment, 52, 24, 10.1016/j.jsat.2014.11.007 · DOI
- Rigal, 2015, Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: a retrospective study, Alcohol and Alcoholism (Oxford, Oxfordshire), 50, 551, 10.1093/alcalc/agv052 · DOI
- Rolland, 2017, Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol, Expert Opinion on Drug Safety, 16, 125
- Simioni, 2016, Characteristics of patients with alcohol dependence seeking baclofen treatment in France: a two-centre comparative cohort study, Alcohol and Alcoholism (Oxford, Oxfordshire), 51, 664, 10.1093/alcalc/agw011 · doi:10.1093/alcalc/agw011
- Vourc'h, 2016, Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial, Trials, 17, 415, 10.1186/s13063-016-1539-2 · DOI
- Addolorato, 2002, Rapid suppression of alcohol withdrawal syndrome by baclofen, American Journal of Medicine, 112, 226, 10.1016/S0002-9343(01)01088-9 · DOI
- Addolorato, 2003, Suppression of alcohol delirium tremens by baclofen administration: a case report, Clinical Neuropharmacology, 26, 258, 10.1097/00002826-200309000-00010 · DOI · Paper page
- Amato, 2011, Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008537.pub2 · DOI · Paper page
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
- Bowery, 1987, GABAA and GABAB receptor site distribution in the rat central nervous system, Neuroscience, 20, 365, 10.1016/0306-4522(87)90098-4 · DOI · Paper page
- Carter, 2009, Behavioral analyses of GHB: receptor mechanisms, Pharmacology & Therapeutics, 121, 100, 10.1016/j.pharmthera.2008.10.003 · DOI · Paper page
- Colombo, 2000, Ability of baclofen in reducing alcohol intake and withdrawal severity: I - preclinical evidence, Alcoholism, Clinical and Experimental Research, 24, 58
- Davidoff, 1985, Antispasticity drugs: mechanisms of action, Annals of Neurology, 17, 107, 10.1002/ana.410170202 · DOI · Paper page
- Dissanaike, 2006, An ethanol protocol to prevent alcohol withdrawal syndrome, Journal of the American College of Surgeons, 203, 186, 10.1016/j.jamcollsurg.2006.04.025 · DOI
- Dodd, 2000, Glutamate-mediated transmission, alcohol, and alcoholism, Neurochemistry International, 37, 509, 10.1016/S0197-0186(00)00061-9 · DOI · Paper page
- Fiellin, 2002, Risk for delirium tremens in patients with alcohol withdrawal syndrome, Substance Abuse, 23, 83, 10.1080/08897070209511478 · DOI · Paper page
- Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Knapp, 2007, Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal, Alcoholism, Clinical and Experimental Research, 31, 582, 10.1111/j.1530-0277.2007.00342.x · DOI
- Leggio, 2008, New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications, Biological Psychiatry, 32, 1106
- Lejoyeux, 1998, Benzodiazepine treatment for alcohol-dependent patients, Alcohol and Alcoholism (Oxford, Oxfordshire), 33, 563, 10.1093/alcalc/33.6.563 · DOI · Paper page
- Lerner, 1985, The alcohol withdrawal syndrome, New England Journal of Medicine, 313, 951, 10.1056/NEJM198510103131509 · DOI
- Liang, 2004, Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence, Journal of Pharmacology and Experimental Therapeutics, 310, 1234, 10.1124/jpet.104.067983 · DOI
- McDonald, 2008, Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats, Psychopharmacology, 197, 591, 10.1007/s00213-008-1077-z · DOI
- Minozzi, 2010, Anticonvulsants for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005064.pub3 · DOI · Paper page
- Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
- Stallings, 2007, Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review, Journal of Oklahoma State Medical Association, 100, 354
- Weiss, 2002, Behavioral neurobiology of alcohol addiction: recent advances and challenges, Journal of Neuroscience, 22, 3332, 10.1523/JNEUROSCI.22-09-03332.2002 · DOI · Paper page
- Westerink, 1996, The pharmacology of mesolimbic dopamine neurons: a dual-probe micro dialysis study in the ventral tegmental area and nucleus accumbens of the rat brain, Journal of Neuroscience, 16, 2605, 10.1523/JNEUROSCI.16-08-02605.1996 · DOI · Paper page
- Liu, 2010, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502 · DOI
- Liu, 2011, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502.pub2 · DOI
- Liu, 2013, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502.pub3 · DOI
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Breaking the loop: Oxytocin as a potential treatment for drug addiction
McGregor, I. S., & Bowen, M. T. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.001 · Cited by 268
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Baclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik, M., Gold, M. S., & Fuehrlein, B. (2024) · Brain Sciences · doi:10.3390/brainsci14030294 · Cited by 25
Metadata
- Authors
- Liu, J., & Wang, L.-N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-08-20
- Volume
- 2019
- Issue
- 11
- Pages
- CD008502-CD008502
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1589454228
- Cited by
- 102
- References
- 7
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Update notices
- new_version (2019-11-06)
- Open access
- green
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- onlinelibrary.wiley.com/termsAndConditions (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.